Immunitybio Inc (IBRX)

$2.44 +0.04 (1.46%)
Market Cap 2.27B
Revenue (ttm) 14.75M
Net Income (ttm) -413.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,803.80%
Debt to Equity Ratio 0.00
Volume 4,761,600
Avg Vol 8,477,744
Day's Range N/A - N/A
Shares Out 945.26M
Stochastic %K 32%
Beta 0.12
Analysts Strong Sell
Price Target $11.40

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
AztecPyramid
AztecPyramid Aug. 9 at 7:38 PM
$IBRX TanyaLA
0 · Reply
snart
snart Aug. 9 at 6:17 PM
$IBRX https://thehill.com/policy/healthcare/5444760-fda-reinstates-vinay-prasad/amp/
1 · Reply
Turnpiker
Turnpiker Aug. 9 at 6:15 PM
$IBRX For your weekend entertainment https://cityquiz.io/quizzes/usa
0 · Reply
TonyLA
TonyLA Aug. 9 at 5:53 PM
$IBRX Even a lovely Saturday this stinker reeks.
0 · Reply
RoyalFlushIBRX
RoyalFlushIBRX Aug. 9 at 4:40 PM
$IBRX 24 Days!
2 · Reply
arnolddiver
arnolddiver Aug. 9 at 4:24 PM
$IBRX Calley Means becoming RFK Jr’s HHS chief of staff bearish or bullish? If memory serves me right, Calley was Pat’s Cancer Decoded guest who described the horrible chemo experience his mother went thru with pancreatic cancer. https://x.com/lauraloomer/status/1954207694975570414?s=46
4 · Reply
CagedMoney
CagedMoney Aug. 9 at 4:10 PM
$IBRX RFK is a twat… fight me 😂
2 · Reply
johnnyta
johnnyta Aug. 9 at 3:50 PM
$IBRX Vinay Prasad's back at FDA. Bullish or bearish?
1 · Reply
daiht1
daiht1 Aug. 9 at 3:45 PM
$IBRX
0 · Reply
svertical1
svertical1 Aug. 9 at 3:40 PM
$IBRX Deaths are mostly among immune compromised…… Bioshield- why not try? https://www.foxnews.com/health/more-cases-deadly-flesh-eating-bacterial-infection-popular-vacation-destination
0 · Reply
Latest News on IBRX
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Aug 5, 2025, 7:00 AM EDT - 4 days ago

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Jul 25, 2025, 6:03 AM EDT - 15 days ago

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Jul 25, 2025, 6:00 AM EDT - 15 days ago

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

Jul 21, 2025, 10:45 AM EDT - 19 days ago

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jul 7, 2025, 9:43 PM EDT - 4 weeks ago

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 12, 2025, 9:09 AM EDT - 2 months ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 3, 2025, 8:45 AM EDT - 2 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

Jun 2, 2025, 9:00 AM EDT - 2 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 27, 2025, 8:00 AM EDT - 2 months ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 12, 2025, 6:30 AM EDT - 3 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 5:05 PM EDT - 3 months ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 9:21 AM EDT - 3 months ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

May 5, 2025, 6:30 AM EDT - 3 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29, 2025, 12:50 PM EDT - 3 months ago

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Apr 28, 2025, 8:30 AM EDT - 3 months ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Apr 21, 2025, 4:21 PM EDT - 3 months ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 15, 2025, 8:00 AM EDT - 4 months ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

Apr 8, 2025, 7:30 AM EDT - 4 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Apr 7, 2025, 5:00 AM EDT - 4 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

ImmunityBio: Taking Care Of Business

Apr 3, 2025, 5:54 PM EDT - 4 months ago

ImmunityBio: Taking Care Of Business

ImmunityBio to Host Investor Day

Mar 26, 2025, 6:00 AM EDT - 4 months ago

ImmunityBio to Host Investor Day

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Mar 13, 2025, 9:00 AM EDT - 5 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 7, 2025, 1:47 AM EST - 5 months ago

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Mar 3, 2025, 7:30 AM EST - 5 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Feb 27, 2025, 7:10 PM EST - 5 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 19, 2025, 9:00 AM EST - 6 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 13, 2025, 3:05 PM EST - 6 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 29, 2025, 8:30 AM EST - 6 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 27, 2025, 9:00 AM EST - 6 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17, 2025, 2:05 PM EST - 7 months ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 16, 2025, 2:25 PM EST - 7 months ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 7 months ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 15, 2025, 5:20 PM EST - 7 months ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Jan 6, 2025, 9:00 AM EST - 7 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Dec 16, 2024, 12:24 AM EST - 8 months ago

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

Dec 13, 2024, 2:40 PM EST - 8 months ago

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Dec 12, 2024, 8:00 AM EST - 8 months ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Dec 11, 2024, 7:30 AM EST - 8 months ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Dec 10, 2024, 4:24 PM EST - 8 months ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

Nov 21, 2024, 10:00 AM EST - 9 months ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Nov 19, 2024, 9:00 AM EST - 9 months ago

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Nov 19, 2024, 8:00 AM EST - 9 months ago

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

ImmunityBio Reports Third-Quarter 2024 Financial Results

Nov 12, 2024, 7:15 AM EST - 9 months ago

ImmunityBio Reports Third-Quarter 2024 Financial Results

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

Oct 28, 2024, 7:53 AM EDT - 10 months ago

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

Oct 25, 2024, 8:22 AM EDT - 10 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

SRRK

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Oct 24, 2024, 9:00 AM EDT - 10 months ago

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio

Oct 23, 2024, 3:35 PM EDT - 10 months ago

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Oct 21, 2024, 9:00 AM EDT - 10 months ago

ImmunityBio to Participate in the Jefferies London Healthcare Conference

ImmunityBio: Moving The Needle

Oct 7, 2024, 11:18 AM EDT - 10 months ago

ImmunityBio: Moving The Needle

AztecPyramid
AztecPyramid Aug. 9 at 7:38 PM
$IBRX TanyaLA
0 · Reply
snart
snart Aug. 9 at 6:17 PM
$IBRX https://thehill.com/policy/healthcare/5444760-fda-reinstates-vinay-prasad/amp/
1 · Reply
Turnpiker
Turnpiker Aug. 9 at 6:15 PM
$IBRX For your weekend entertainment https://cityquiz.io/quizzes/usa
0 · Reply
TonyLA
TonyLA Aug. 9 at 5:53 PM
$IBRX Even a lovely Saturday this stinker reeks.
0 · Reply
RoyalFlushIBRX
RoyalFlushIBRX Aug. 9 at 4:40 PM
$IBRX 24 Days!
2 · Reply
arnolddiver
arnolddiver Aug. 9 at 4:24 PM
$IBRX Calley Means becoming RFK Jr’s HHS chief of staff bearish or bullish? If memory serves me right, Calley was Pat’s Cancer Decoded guest who described the horrible chemo experience his mother went thru with pancreatic cancer. https://x.com/lauraloomer/status/1954207694975570414?s=46
4 · Reply
CagedMoney
CagedMoney Aug. 9 at 4:10 PM
$IBRX RFK is a twat… fight me 😂
2 · Reply
johnnyta
johnnyta Aug. 9 at 3:50 PM
$IBRX Vinay Prasad's back at FDA. Bullish or bearish?
1 · Reply
daiht1
daiht1 Aug. 9 at 3:45 PM
$IBRX
0 · Reply
svertical1
svertical1 Aug. 9 at 3:40 PM
$IBRX Deaths are mostly among immune compromised…… Bioshield- why not try? https://www.foxnews.com/health/more-cases-deadly-flesh-eating-bacterial-infection-popular-vacation-destination
0 · Reply
daiht1
daiht1 Aug. 9 at 2:33 PM
$IBRX Unsure why the Ibrx board sentiments turned red/bearish, any negative catalysts except maybe dilution again?
3 · Reply
RKwine
RKwine Aug. 9 at 2:16 PM
$IBRX good morning, very bullish
0 · Reply
JoeMama777
JoeMama777 Aug. 9 at 2:15 PM
$IBRX Company is up against alot of money for oncologists on the chemo side. ”Oncologists bill separately for chemotherapy drugs and make a considerable margin, which explains why they never fail to recommend them. Cancer infusion centers are hugely profitable. One doctor can prescribe chemotherapy and oversee a dozen or more treatments per hour.” https://x.com/dramerling/status/1954161864318844952?s=46
3 · Reply
Eureka2005
Eureka2005 Aug. 9 at 2:12 PM
$IBRX Everything indicates that in the coming days the COVID-19 vaccine that Immunitybio once offered and was rejected will be claimed. Written in 2021: “This T cell epitope analysis provides additional evidence of the potential for the vaccine candidate to serve as an universal booster for patients who have received an initial S protein only vaccine by not only fortifying S activated T cells, but also broadening protection by the addition of N activated T cells. This could provide additional protection against variants and longer-term protection against the virus.”
2 · Reply
GladlyPayYouTuesday
GladlyPayYouTuesday Aug. 9 at 1:43 PM
$IBRX for those of us who aren't doctors, is RFKjr's latest comments good or bad for IBRX? Thanks in
1 · Reply
Runmaster83
Runmaster83 Aug. 9 at 1:29 PM
$IBRX Still no X posts from PSS since the 4th. Looking more and more like a quiet period to me.
2 · Reply
Outdoors
Outdoors Aug. 9 at 1:12 PM
$IBRX One of my sons looking to move to Virginia from California returned home with Covid. He and wife treated themselves, vitamins blah blah. Took their young child to hospital, fighting to breathe, throwing up. Oxygen and steroids was treatment. Apparently Covid is still a thing. What’s the answer to this?
6 · Reply
Stocktud
Stocktud Aug. 9 at 12:19 PM
$IBRX I wonder if our vaccine is also Anti Aging effective? If so, I want the vaccine really bad.
1 · Reply
svertical1
svertical1 Aug. 9 at 11:42 AM
$IBRX “We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,” Kennedy stated this week. What other candidate(s)/platform(s) other than Bioshield? The ‘s’ implies more than one. Haha
1 · Reply
Stocktud
Stocktud Aug. 9 at 11:17 AM
$IBRX load up bros! This is an inconceivable price for this stock. Target 40,000 shares
0 · Reply
YeboGogo
YeboGogo Aug. 9 at 11:13 AM
$IBRX "Follow the science"... Mmm, where have I heard that before 🤔... https://x.com/SecKennedy/status/1953847258060833059
0 · Reply
LadyQRex
LadyQRex Aug. 9 at 11:06 AM
$IBRX - This Simply Wall Street article paints a transparent but overall positive picture of IBRX’s financials: https://www.webullapp.com/news-detail/13294588523742208?theme=1&hl=en&color=2&_v=1&tickerId=913256050&disSymbol=IBRX&sourcePage=Stock_NewsList&sp=0&hl=en News Detail Any thoughts?
0 · Reply